Case Studies reported in her medical history but was not identified on the initial urinalysis findings (the urine specimen color was yellow); however, her urinalysis results revealed an elevated hemoglobin level via dipstick testing, which was confirmed by microscopic examination of the urine. The patient reported no other urinary or systemic symptoms, such as dysuria, fever, chills, night sweats, or weight loss. On urinalysis, the leukocyte esterase and nitrite results were negative, the urine white blood cell count was not increased, and the urine protein level was within normal limits. The blood urea nitrogen and creatinine levels were also within normal limits ( Table 1) . The imaging studies identified a mass in the superior pole of the right kidney.
2. Common etiologies for hematuria include urinary tract infection (UTI), calculi, glomerular disease, menstrual-bleeding contamination, and malignant neoplasms. In a prospective analysis of 1930 patients with hematuria, 1 it was revealed that 13% had UTIs, 12% had bladder tumors, 10% had nephrologic diseases, 2% had kidney stones, 0.6% had kidney tumors, and 0.1% had upper tract urothelial carcinoma. Of note, for 61% of patients, no cause was identified for hematuria. 1 An occult UTI may be asymptomatic; however, dysuria and fever are commonly observed in conjunction with hematuria. One would also expect to observe the presence of pyuria and hematuria, as well as positive leukocyte esterase and nitrite test results. Renal calculi commonly present with gross hematuria; patients with these conditions typically experience unilateral flank pain. In glomerular disease, azotemia would be expected, along with some degree of proteinuria, dysmorphic red blood cells, and red cell casts on urine microscopic examination. Menstrual contamination is a common cause of false hematuria; hematuria is rarely associated with urinary tract endometriosis. 2 Gross hematuria, one of the 6 sickle-cell nephropathic manifestations described by Berman in 1974, is often associated with sickle cell trait. 3, 4 The other sickle cell nephropathic manifestations described in the literature include papillary necrosis, nephrotic syndrome, renal infarction, inability to produce concentrated urine, and pyelonephritis. 3 Davis et al 4 describe renal medullary carcinoma as the seventh known sickle cell nephropathic manifestation. Hematuria is usually benign and most likely occurs due to bleeding beneath the renal pelvic epithelium.
Occult malignant neoplasms are also a common cause of painless hematuria. The primary tumor can grow anywhere along the urinary tract, including the bladder, ureter, or kidney. The most common malignant neoplasm observed with hematuria is bladder cancer. 1 It is uncommon that hematuria is associated with an upper urinary tract malignant neoplasm. 1 Our patient has a mass in her right kidney that was potentially responsible for her gross hematuria.
3. To further evaluate the mass in the patient's right kidney, a histologic diagnosis is necessary. In a series of 2675 renal masses, 88% were proven to be malignant and 12% to be benign; as the size of the mass increased, so did the risk of malignancy. 5 Smaller tumors were less likely to be malignant then larger tumors; however, of tumors less than 1 cm in diameter, 62% were malignant. 5 Our patient's tumor was 3.9 cm in diameter, as determined by CT scan; it had an 87% risk of being malignant. 5 Due to the high risk of malignancy, a histologic diagnosis was sought.
Clear cell renal cell carcinoma (RCC) is the most common malignant renal tumor (71%), followed by papillary RCC (14%), chromophobe RCC Case Studies (10%), unclassified (4%), and collecting duct RCC (<1%). 5 The most common types of benign tumors include oncocytoma (74%), angiomyolipoma (11%), metanephric adenoma (3%), and others (12%). 5 To rule out malignancy, a CT scan-guided core biopsy was attempted; however, the results did not yield a diagnosis. A right nephrectomy was subsequently performed for definitive histologic diagnosis, based on the presumptive risk of malignancy.
4. The right kidney resection specimen revealed a wellcircumscribed, firm, yellowish-tan mass, with areas of hemorrhage present in the upper lobe; it measured 3.7 × 3.5 × 2.0 cm (Image 1). The mass pushed against but did not grossly invade the renal capsule; however, the renal capsule firmly adhered to the mass (Image 2). The mass appeared to originate from the renal medulla; no evidence of renal vascular invasion was observed.
On microscopic inspection, the tumor had a predominantly tubulopapillary growth pattern; certain areas had a reticular yolk sac pattern within a desmoplastic stroma (Image 3 and Image 4). The tumor subtly permeated the surrounding renal parenchyma. In the renal collecting ducts, tubules with dysplastic epithelium were observed. Nuclei lining the tubules were extremely pleomorphic, with vesicular to coarse chromatin, prominent nucleoli, and mitotic figures (Image 5). Sickled erythrocytes were identified within the dilated tubules (Image 6). Microscopic invasion of the renal capsule was identified at the
Image 1
The right kidney resection specimen revealed a well-circumscribed, firm, yellowish-tan mass, with areas of hemorrhage, present in the upper lobe, measuring 3.7 × 3.5 × 2.0 cm.
Image 2
Adherence of the renal capsule firmly adheres to this location to the upper lobe of the kidney. 
Image 3
Predominantly tubulopapillary growth pattern of tumor (H&E staining; magnification, ×100).
Image 4
Reticular yolk sac pattern of tumor within a desmoplastic stroma (H&E staining; magnification, ×200).
Image 5
The nuclei lining the tubules, which are extremely pleomorphic, with vesicular to coarse chromatin, prominent nucleoli, and mitotic figures (H&E staining; magnification, ×200).
Image 6
Sickled erythrocytes identified within the dilated tubules (H&E staining; magnification, ×400).
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The histologic picture in this case is most consistent with collecting duct RCC or renal medullary carcinoma (RMC). These entities commonly have a tubulopapillary growth pattern, including high-grade pleomorphic cells with prominent nucleoli. Immunohistochemistry cannot differentiate between these 2 entities, to our knowledge; hence, additional history and histologic clues must be considered. First, the patient has a history of sickle cell trait. Second, sickled erythrocytes are present within the high-grade tumor. This combination of factors is most consistent with RMC. This diagnosis was confirmed by an expert consultant.
RMC was first described in 1995 by Davis et al 4 of the Armed Forces Institute of Pathology (AFIP) as the seventh sickle cell nephropathy. RMC is observed most often in young African American males with sickle cell trait. 4, 7 It has also been described 4, [7] [8] [9] in sickle cell disease and hemoglobin SC disease. The male to female ratio for this disease is 1.9:1; however, in patients younger than 9 years of age, this ratio is 5:1. The mean age at diagnosis is 19 years (range, 5-40 years). 7 One case has been reported of a 69-year-old Afrobrazilian woman with sickle cell trait who also had conventional renal cell carcinoma. 10 Common symptoms of RMC include hematuria, flank pain, and weight loss. 4, 7 RMC has the characteristic histologic pattern of reticular growth similar to yolk sac testicular tumors of reticular type. 10 Additional patterns have been described, including tubular, solid, adenoid cystic, sarcomatoid, and microcystic with micropapillations. 4, 10 Also characteristic of this disease is prominent stromal desmoplasia, 4, 10 which can be collagenous, edematous, mucoid, or myxoid. 10 Sickled erythrocytes are usually identified in the tissues; invasion of the renal parenchyma is almost universally present. 4, 9, 10 The appearance of these tumor cells is high-grade and characterized by dark eosinophilic cytoplasm with large pleomorphic nuclei and prominent nucleoli. 4, [9] [10] [11] Rhabdoid-like cells have also been identified in these tumors. 9, 10, 12 Given the characteristic morphologic characteristics of the specimen and the patient's history of a sickling disorder, the diagnosis of RMC can be made without ancillary tests in this case.
RMC is thought to be derived from the epithelium of the collecting ducts near the renal papillae. The acidic, hypertonic, and hypoxic microenvironment of the renal medulla promotes sickling of susceptible erythrocytes. Further, it has been proposed 9 that hypoxia-inducible factor (HIF, OMIM#603348), a transcription factor that regulates gene expression in hypoxia, is induced in the renal medulla microenvironment. HIF induces tumor protein 53 (TP53, OMIM#191170) expression, which leads to apoptosis. In tumors lacking p53, the expression HIF induces the angiogenic factor vascular endothelial growth factor (VEGF, OMIM #192240). VEGF subsequently upregulates BCL-2 (OMIM #151430), which inhibits apoptosis. One proposed molecular mechanism for RMC pathogenesis relies on the expressions of VEGF, HIF, and TP53.
Immunohistochemical profiling of RMC has shown that it expresses cytokeratin pool (AE1/AE3), low-molecularweight cytokeratins (CAM 5.2, 35BetaH11), and epithelial membrane antigen. 9 Coexpression of vimentin is also common.
12 High molecular weight cytokeratins, which are usually undetectable or only weakly positive, 9, 10, 12 have shown that RMC loses the expression of INI1, as demonstrated by immunohistochemical staining. Loss of INI1 is not associated with high-grade renal cell carcinomas or urothelial carcinomas of the renal pelvis, including those with rhabdoid features. 12 No studies have been published, to our knowledge, that directly compare immunohistochemical profiles of collecting duct RCC and RMC. The results of immunohistochemical studies published have not identified a pattern that can differentiate between collecting duct RCC and RMC.
6. The skin biopsy results were morphologically similar to that of the renal cells; the results were consistent with metastatic RMC (Image 7). RMC is an aggressive tumor; it is metastatic in 95% of patients at the time of diagnosis. 7 Our case is unique because the patient had no evidence of metastatic disease at the time of diagnosis or on initial follow-up; however, she developed widespread metastatic disease within months after her initially negative PET result, which attests to the aggressive nature of the disease. RMC is prone to metastasize to the lymph nodes, lungs, 4,7,13,14 and liver. 4, 7 Although RMC commonly metastasizes to the adrenal glands, 4, 7, 15, 16 bone, 10 vertebrae, 10 vagina, 16 ovaries, 16 and orbit, 17 this is the first case study, to our knowledge, of RMC metastasizing to the skin. 18 7. Survival after diagnosis in one study was 15 weeks, but more recent data shows a mean survival of 19 weeks (range, 2-60 weeks). 7 Four cases have been reported of long-term disease free survival (1 case for 2 years; 19 2 cases for 2 years, 9 months; 7 and 1 case for 8 years 10 ). This patient survived 3 years 1 month from the time of initial diagnosis, making this one of the few cases of relatively long-term survival. Patients who have survived this disease for prolonged periods of time had localized involvement at the time of diagnosis and were treated with radical nephrectomy. 7, 10, 19 Also, Simpson et al 7 reported a case in which a patient had no evidence of metastasis after treatment and later developed widespread metastatic disease. This suggests the possibility of a cohort of patients with localized disease that can be successfully treated with surgical intervention; however, as our case demonstrates, close follow-up is necessary because widespread metastatic disease can develop even after the patient is clinically and radiologically free of the disease. LM
